Zenas BioPharma | LinkedIn (original) (raw)

Biotechnology Research

Waltham, MA 6,855 followers

Enabling patients with autoimmune diseases to reimagine life

About us

Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Waltham, MA

Type

Public Company

Specialties

Autoimmune Diseases and Immunology

Locations

Employees at Zenas BioPharma

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding